# Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome

> **NCT05377112** · EARLY_PHASE1 · COMPLETED · sponsor: **Synlogic** · enrollment: 11 (actual)

## Conditions studied

- Enteric Hyperoxaluria

## Interventions

- **DRUG:** SYNB8802v1
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05377112
- **Lead sponsor:** Synlogic
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-29
- **Primary completion:** 2022-12-07
- **Final completion:** 2022-12-07
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05377112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05377112, "Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05377112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*